Human Immunodeficiency Virus Drugs Market Share,Forecast Advancement, Target Audience, Growth Prospects and Segmentation | COVID-19 Effects
Human Immunodeficiency Virus Drugs Market Overview
HIV drugs are medicines prescribed to patients diagnosed with HIV as part of
their treatment. The drugs are known as antiretrovirals. The global HIV drugs
market report by Market Research Future (MRFR) takes into consideration the
various developments in drugs and treatment for the disease and projects
revenue and growth estimations for the period of 2022 to 2030 (forecast
period). It even takes into view the impact of COVID-19 and its aftermath on
the production cycle of branded and generic drugs.
The global Human
Immunodeficiency Virus Drugs Market Share can reach a valuation of USD
30141.25 Million by 2030. It is predicted to expand at a CAGR of 3.9% over the
forecast period.
Major factors driving market growth are high prevalence of HIV infections
and awareness of new treatment for HIV. In 2018, the number of HIV patient
numbers had inflated to 1.7 million. Owing to awareness of treatment for HIV,
the rise in number of individuals undergoing treatment has shot up. Nearly 23.3
million patients are undergoing antiretroviral therapy (ART) in 2018. Approval
of new drugs by drug regulatory bodies as well as suggestion for combinations
of treatment can fuel market sales.
Launch of new drugs for lowering treatment costs and providing relief to
patients will be lucrative for the market in the long run. Other factors to
encourage growth include research and development into new drugs, clinical
trials for said drugs, and rise in government initiatives for creating
awareness of the disease and its existing treatment options.But product recalls
and strict regulatory policies can restrain market growth.
Human Immunodeficiency Virus Drugs Market Segmentation
The global Human
Immunodeficiency Virus Drugs Market Trends has been segmented by type and
end-user.
By type, it is segmented into CCR5 antagonist, integrase inhibitors,
protease inhibitors, fusion inhibitors, post-attachment inhibitor or monoclonal
antibody, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and
non-nucleoside reverse transcriptase inhibitors (NNRTIs). NRTIs accounted for a
large market and predicted to dominate the market till 2023. These drugs
prevent HIV’s transcriptase from copying its RNA into DNA of the human body.
Launch of generic drugs by prominent pharmaceutical bigwigs such as Lupin can
drive the segment growth. Protease inhibitors can capture a major chunk of the
global HIV drugs market owing to its ability to prevent HIV from infecting
other healthy cells.
By end-user, it is divided into specialty centers and hospitals &
clinics. Hospitals & clinics held the largest market share and will
continue its dominant streak owing to patients coming to hospitals for
first-hand diagnosis and treatment options. On the other hand, specialty centers
can also encourage growth of the global HIV drugs market by providing treatment
entirely on HIV.
Human Immunodeficiency Virus Drugs Market Regional Analysis
Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa
(MEA) are regions taken into consideration with respect to the global HIV drugs
market.
Americas held the largest market share owing to the huge prevalence of AIDS
in cities. Development of long-acting drugs for preventing the chances of HIV
infections among the unaffected will facilitate market growth. In addition, the
mutated versions of HIV strains which are resistant to existing drugs are
concerning to patients.
APAC is expected to display the fastest growth rate during the forecast
period owing to a significant HIV patient pool and awareness of HIV treatment
options. The outbreak of the COVID-19 pandemic has led to medical regulatory
bodies for relying on HIV drugs in combination with others for rapid recovery
of patients. In April 2020, the Indian Council of Medical Research (ICMR) has decided
to use HIV drugs in combination with FDA approved drugs for preventing
replication of the COVID-19 virus in humans.
Competition Outlook
Human Immunodeficiency Virus Drugs Market Players Gilead Sciences, Inc.,
Boehringer Ingelheim International GmbH, Aurobindo Pharma, Pfizer Inc., ViiV
Healthcare, Celltrion Healthcare Co., Ltd, Bristol-Myers Squibb Company,
Hoffmann-La Roche Ltd, Cipla Inc., Merck & Co., Inc., Teva Pharmaceutical
Industries Ltd, and AbbVie Inc. are key players of the global HIV drugs
market.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private
Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
.jpg)
Comments
Post a Comment